{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:03:16Z","timestamp":1783702996516,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K06799"],"award-info":[{"award-number":["JP18K06799"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.dmpk.2023.100537","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T14:25:33Z","timestamp":1699367133000},"page":"100537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil"],"prefix":"10.1016","volume":"54","author":[{"given":"Kenjiro","family":"Okubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Nakauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Tsujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Goda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinatsu","family":"Otake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-6793","authenticated-orcid":false,"given":"Kosho","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5965-3987","authenticated-orcid":false,"given":"Hideyo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyomi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2023.100537_bib1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2023.100537_bib2","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/bcp.13914","article-title":"Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers","volume":"85","author":"Funakoshi","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.1999.00005.x","article-title":"Comparison of (S)-mephenytoin and proguanil oxidation in\u00a0vitro: contribution of several CYP isoforms","volume":"48","author":"Coller","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib4","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/cpt.863","article-title":"Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype","volume":"103","author":"Kagami","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2023.100537_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.2011.127","article-title":"Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects","volume":"90","author":"Simon","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2023.100537_bib6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1124\/dmd.111.041293","article-title":"The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel","volume":"39","author":"Ogilvie","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2023.100537_bib7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00228-022-03313-2","article-title":"Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : influence of alternate-day dosing of vonoprazan","volume":"78","author":"Higuchi","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s13318-018-0521-7","article-title":"In\u00a0vitro assessment of potential for CYP-inhibition-based drug-drug interaction between vonoprazan and clopidogrel","volume":"44","author":"Nishihara","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.dmpk.2023.100537_bib9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/00498254.2016.1203505","article-title":"In\u00a0vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker","volume":"47","author":"Yamasaki","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2023.100537_bib10","series-title":"inventors, Shanghai Glass Medical Technology Co Ltd, assignee. Substituted azole -4- alkyl amine compounds and application thereof","author":"Wang","year":"2018"},{"key":"10.1016\/j.dmpk.2023.100537_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tet.2022.132669","article-title":"Identification, characterization, synthesis of major metabolites biotransformed from vonoprazan fumarate","volume":"108","author":"Lin","year":"2022","journal-title":"Tetrahedron"},{"key":"10.1016\/j.dmpk.2023.100537_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00498254.2015.1071502","article-title":"Effect of buffer conditions on CYP2C8-mediated paclitaxel 6\u03b1-hydroxylation and CYP3A4-mediated triazolam \u03b1- and 4-hydroxylation by human liver microsomes","volume":"46","author":"Kudo","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2023.100537_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1023\/A:1023294632129","article-title":"Analysis of nonlinear and nonsteady state hepatic extraction with the dispersion model using the finite difference method","volume":"26","author":"Hisaka","year":"1998","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.dmpk.2023.100537_bib14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/psp4.12939","article-title":"Tiered approach to evaluate the CYP3A victim and perpetrator drug\u2013drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling","volume":"12","author":"Mulford","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s11095-008-9607-2","article-title":"The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling","volume":"25","author":"Kato","year":"2008","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.dmpk.2023.100537_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/cpt1974161part187","article-title":"Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model","volume":"16","author":"Benowitz","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2023.100537_bib17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jps.10128","article-title":"Prediction of pharmacokinetics prior to in\u00a0vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition","volume":"91","author":"Poulin","year":"2002","journal-title":"J\u00a0Pharmaceut Sci"},{"key":"10.1016\/j.dmpk.2023.100537_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2023.100537_bib19","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpt.1128","article-title":"OCT1 deficiency affects hepatocellular concentrations and pharmacokinetics of cycloguanil, the active metabolite of the antimalarial drug proguanil","volume":"105","author":"Matthaei","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmpk.2023.100537_bib20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/bdd.711","article-title":"Prediction of human blood-to-plasma drug concentration ratio","volume":"31","author":"Uchimura","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmpk.2023.100537_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200140050-00003","article-title":"Pharmacokinetic interactions of antimalarial agents","volume":"40","author":"Giao","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2023.100537_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1365-2125.1987.tb03245.x","article-title":"Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects","volume":"24","author":"Wattanagoon","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2133\/dmpk.18.365","article-title":"The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.dmpk.2023.100537_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s002280050544","article-title":"Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro","volume":"54","author":"Rasmussen","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/00034983.1946.11685302","article-title":"The absorption and excretion of paludrine in the human subject","volume":"40","author":"Maegraith","year":"1946","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.dmpk.2023.100537_bib26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1152\/ajplegacy.1969.217.6.1639","article-title":"Active transport of tertiary amine compounds into bile","volume":"217","author":"Nayak","year":"1969","journal-title":"Am J Physiol"},{"key":"10.1016\/j.dmpk.2023.100537_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000238597","article-title":"Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man","volume":"34","author":"Edstein","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dmpk.2023.100537_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2125.1995.tb04452.x","article-title":"Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population","volume":"39","author":"Setiabudy","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2125.1996.tb00179.x","article-title":"Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism","volume":"41","author":"Somogyi","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100537_bib30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0026-895X(24)12051-2","article-title":"Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices","volume":"28","author":"Renwick","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2023.100537_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchromb.2016.01.051","article-title":"A\u00a0validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry","volume":"1015\u20131016","author":"Yoneyama","year":"2016","journal-title":"J\u00a0Chromatogr, B: Anal Technol Biomed Life Sci"},{"key":"10.1016\/j.dmpk.2023.100537_bib32","series-title":"Common technical document for vonoprazan fumarate (Takecab tablets 10 mg and 20 mg) 2.6.6.4 pharmaceuticals and medical devices agency of Japan","year":"2014"},{"key":"10.1016\/j.dmpk.2023.100537_bib33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.dmpk.2023.100537_bib34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dmpk.2023.100537_bib35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2023.100537_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2023.100537_bib37","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1124\/dmd.111.040634","article-title":"Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions","volume":"39","author":"Chen","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2023.100537_bib38","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in\u00a0vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res (N Y)"},{"key":"10.1016\/j.dmpk.2023.100537_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12936-017-2062-y","article-title":"Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates","volume":"16","author":"van der Velden","year":"2017","journal-title":"Malar J"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:23Z","timestamp":1761163043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436723000496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":39,"alternative-id":["S1347436723000496"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100537","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic model analysis of the inhibitory effect of vonoprazan on the metabolic activation of proguanil","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100537"}}